| Multiple Hospitals Acquire Second CyberKnife(R) System To Meet ...
Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Georgetown University Hospital's second CyberKnife(R) Robotic Radiosurgery System has arrived at its Lombardi Comprehensive Cancer Center in Washington, D.C. The system is expected to begin treating patients in July 2007. Georgetown is one of many centers with a second CyberKnife System installed or pending installation in the coming months to meet the growing demand for radiosurgery.
With patient interest in CyberKnife radiosurgery flourishing and physician referrals growing, the addition of a second system at Georgetown is representative of a trend toward multiple systems at active CyberKnife centers worldwide.
-- Sinai Hospital in Baltimore, Md. is awaiting the installation of a second CyberKnife System, which it secured through Accuray's shared ownership program.
UCSF receives $150 million pledge for cancer center
UCSF has received a $150 million pledge to support clinical and research programs of the UCSF Comprehensive Cancer Center. It is the largest philanthropic commitment from an individual ever received by the University and was given anonymously. Already recognized for its research excellence and regarded as one of the most comprehensive programs in the nation, the UCSF Cancer Center will use the gift to strengthen five major components of its programs. The gift will support UCSFs efforts to become a world leader in cancer care and the West Coast hub for experimental therapies in treating cancer patients; develop a world-class database system to support individualized therapies of the future; enhance the Centers ability to recruit top-league scientific leaders; improve patient care and support services; and further strengthen the Centers translation of basic research into clinical care.
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and ...
NEW YORK, June 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced that 4 posters were presented at the 11th International Myeloma Workshop demonstrating the clinical activity of KRX-0401 (perifosine) in patients with advanced multiple myeloma and Waldenstrom's macroglobulinemia. Perifosine is currently being evaluated in 3 ongoing, multi-center clinical studies for patients with relapsed or relapsed/refractory multiple myeloma, including in combination with dexamethasone, in combination with Velcade(R) (bortezomib) and in combination with Revlimid(R) (lenalidomide) plus dexamethasone. Perifosine is also being evaluated in an ongoing phase II single agent study in patients with relapsed and/or refractory Waldenstrom's macroglobulinemia. Data from each of these ongoing studies was presented during the conference and demonstrates perifosine's activity, both as a single agent and as part of a combination, in patients with multiple myeloma and Waldenstrom's macroglobulinemia.
|
